

---

**Form 604**Corporations Law  
Section 671B**Notice of change of interests of substantial holder**

---

To Company Name/Scheme Benitec Biopharma Limited  
ACN/ARSN 068 943 662

**1. Details of substantial holder (1)**

Name JPMorgan Chase & Co. and its affiliates

ACN (if applicable) NA

There was a change in the interests of the  
substantial holder on

13 June 2018

The previous notice was given to the company on

9 May 2018

The previous notice was dated

7 May 2018**2. Previous and present voting power**

The total number of votes attached to all the voting shares in the company or voting interests in the scheme that the substantial holder or an associate (2) had a relevant interest (3) in when last required, and when now required, to give a substantial holding notice to the company or scheme, are as follows:

Class of securities (4)	Previous notice		Present notice	
	Person's votes	Voting power (5)	Person's votes	Voting power (5)
Ordinary	15,444,020	7.00%	15,420,800	6.00%

**3. Changes in relevant interests**

Particulars of each change in, or change in the nature of, a relevant interest of the substantial holder or an associate in voting securities of the company or scheme, since the substantial holder was last required to give a substantial holding notice to the company or scheme are as follows:

Date of change	Person whose relevant interest changed	Nature of change (6)	Consideration given in relation to change (7)	Class and number of securities affected	Person's votes affected
See Appendix	Highbridge Capital Management LLC	In its capacity as investment manager or in various other related capacities	See Appendix	23,220 (Ordinary)	23,220 (Ordinary)

#### 4. Present relevant interests

Particulars of each relevant interest of the substantial holder in voting securities after the change are as follows:

Holder of relevant interest	Registered holder of securities	Person entitled to be registered as holder (8)	Nature of relevant interest (6)	Class and number of securities	Person's votes
Highbridge Capital Management LLC	Credit Suisse Securities (USA) LLC	Various clients and custodians	In its capacity as investment manager or in various other related capacities	15,420,800 (Ordinary)	15,420,800 (Ordinary)

#### 5. Changes in association

The persons who have become associates (2) of, ceased to be associates of, or have changed the nature of their association (9) with, the substantial holder in relation to voting interests in the company or scheme are as follows:

Name and ACN (if applicable)	Nature of association
Highbridge Capital Management LLC	Subsidiary of JPMorgan Chase & Co.

#### 6. Addresses

The addresses of persons named in this form are as follows:

Name	Address
JPMorgan Chase & Co.	270 Park Avenue, New York 10017, United States
Highbridge Capital Management LLC	40 West 57 <sup>TH</sup> Street – 32 <sup>ND</sup> Floor, New York 10019

#### Signature

**Print name** Neha Sangani **Capacity** JPMorgan Chase Bank, N.A.

**Sign here**

**Date** 14/June/2018

#### DIRECTIONS

- (1) If there are a number of substantial holders with similar or related relevant interests (eg. a corporation and its related corporations, or the manager and trustee of an equity trust), the names could be included in an annexure to the form. If the relevant interests of a group of persons are essentially similar, they may be referred to throughout the form as a specifically named group if the membership of each group, with the names and addresses of members is clearly set out in paragraph 6 of the form.

- (2) See the definition of "associate" in section 9 of the Corporations Law.
- (3) See the definition of "relevant interest" in sections 608 and 671B(7) of the Corporations Law.
- (4) The voting shares of a company constitute one class unless divided into separate classes.
- (5) The person's votes divided by the total votes in the body corporate or scheme multiplied by 100.
- (6) Include details of:
  - (a) any relevant agreement or other circumstances because of which the change in relevant interest occurred. If subsection 671B(4) applies, a copy of any document setting out the terms of any relevant agreement, and a statement by the person giving full and accurate details of any contract, scheme or arrangement, must accompany this form, together with a written statement certifying this contract, scheme or arrangement; and
  - (b) any qualification of the power of a person to exercise, control the exercise of, or influence the exercise of, the voting powers or disposal of the securities to which the relevant interest relates (indicating clearly the particular securities to which the qualification applies).

See the definition of "relevant agreement" in section 9 of the Corporations Law.

- (7) Details of the consideration must include any and all benefits, money and other, that any person from whom a relevant interest was acquired has, or may, become entitled to receive in relation to that acquisition. Details must be included even if the benefit is conditional on the happening or not of a contingency. Details must be included of any benefit paid on behalf of the substantial holder or its associate in relation to the acquisitions, even if they are not paid directly to the person from whom the relevant interest was acquired.
- (8) If the substantial holder is unable to determine the identity of the person (eg. if the relevant interest arises because of an option) write "unknown".
- (9) Given details, if appropriate, of the present association and any change in that association since the last substantial holding notice.

BENITEC BIOPHARMA LIMITED (AU000000BLT8)													
Transaction date	Entity	Type of transaction	Equity/ADS	Ccy	Price	Quantity	Equivalent Shares (Number to be received when converted)	Consideration (Total Paid for the ADS)	Total Positions	Issued share capital	% Owned	Highbridge Capital Management LLC	Total
Balance as of 7 May 2018									15,444,020	220,586,754	7.00%	15,444,020	15,444,020
4-Jun-18									15,444,020	257,029,426	6.01%	-	-
13-Jun-18	Highbridge Capital Management LLC	SALE	ADS	AUD	2.35	(1,161)	(23,220)	\$ 54,567.00	15,420,800	257,029,426	6.00%	(23,220)	(23,220)
Balance as of 13 June 2018									15,420,800	257,029,426	6.00%	15,420,800	15,420,800